Rigetti's Expanding Commercial Base Confirms Traction, But Valuation Remains Stretched

What happened

Rigetti Computing's first-half 2026 revenue grew to $9.5 million from $3.3 million a year earlier, driven by on-premises quantum system sales that broadened its customer base, as highlighted in a recent Zacks article. The company's Q2 2026 revenue was $5.1 million, but it still posted a $28.1 million operating loss and a $52.6 million GAAP net loss, reflecting heavy R&D and infrastructure costs. Customer concentration remains extreme, with one customer representing 64% of Q2 revenue, underscoring the lumpy, project-based nature of demand. While the commercial traction is real—backed by an $8.4 million order from C-DAC and deployments like the PSC/HPE testbed—the current $5.5 billion market capitalization prices substantial future success far beyond the current revenue base. Overall, the news reinforces the existing thesis that Rigetti is making incremental progress but remains a speculative play on quantum computing milestones.

Implication

The expanding commercial base is a positive signal, but it does not alter the fundamental risk-reward profile, which remains balanced at current prices. The company's revenue growth is still small and heavily dependent on a few customers, making quarterly results unpredictable and subject to program delays. Key catalysts to monitor include the conversion of the $100 million Department of Commerce LOI into definitive funding, the C-DAC 108-qubit deployment in the second half of 2026, and improvement in 108-qubit fidelity from 99.1% toward 99.5%. Until these milestones are achieved and channel access translates into paid usage or repeat orders, the stock likely remains range-bound and vulnerable to sentiment shifts in the quantum sector. Given the WAIT rating with a trim level above $22 and attractive entry below $13, current prices near $16.50 offer limited upside without confirmation of the bull scenario.

Thesis delta

No material shift in the investment thesis. The news confirms the existing base case of growing but still research-scale commercial traction, which was already factored into the WAIT rating. The absence of new information on key catalysts like CHIPS funding conversion or fidelity improvement means the stock's risk-reward remains unchanged.